hu14.18-IL2

BIOLOGICAL3 trials

Sponsors

University of Wisconsin, Madison

Conditions

MelanomaNeuroblastomaOsteosarcomaRecurrent NeuroblastomaRelapsed Neuroblastoma

Phase 1

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

WithdrawnNCT03209869

University of Wisconsin, MadisonNeuroblastoma, Osteosarcoma, Recurrent Neuroblastoma +1

Start: 2018-03-12End: 2022-09-07Updated: 2022-09-13

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

TerminatedNCT03958383

University of Wisconsin, MadisonMelanoma

Start: 2020-01-30End: 2025-12-09Updated: 2026-06-03

Phase 2

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

CompletedNCT00590824

University of Wisconsin, MadisonMelanoma

Start: 2007-12-17End: 2018-09-20Updated: 2019-11-21

Related Papers

Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.

2024-08-276 citations

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

Journal of Clinical Oncology2021-05-202 citations